Icure Pharmaceutical Inc

Icure Pharmaceutical Inc has a market price of 2,170 KRW and a market capitalization of 81,092,216,450 KRW, with a price-to-book ratio of 3.08 and a price-to-tangible-book ratio of 3.08. The company's enterprise value to revenue is 1.24, and its enterprise value to EBITDA is -4.24, indicating a negative EBITDA. The company's profitability is weak, with a return on equity of -1.2754 and a return on assets of -0.3713. It reported a net loss of 33,600,111,690 KRW and an operating loss of 24,396,747,710 KRW. Gross profit was 4,397,882,950 KRW, but this was insufficient to offset the operating and net losses. Icure Pharmaceutical Inc operates through two segments: Cosmetics and Pharmaceuticals. The Cosmetics segment includes basic cosmetics, mask packs, and patches, while the Pharmaceuticals segment includes OTC and ETC drugs. The company's revenue is distributed across these segments, but the financial snapshot does not provide specific revenue figures for each segment. The company's growth trajectory is uncertain, with a negative operating cash flow of -2,684,810,170 KRW and a free cash flow of -34,013,378,510 KRW. Capital expenditures were -5,478,434,750 KRW, indicating significant investment in the period. The outlook for the current and next fiscal years is not provided in the data. The company faces liquidity and dilution risks. It has a debt-to-equity ratio of 1.17 and a current ratio of 0.59, indicating potential liquidity constraints. The risk assessment flags a negative net cash position after subtracting total debt. The dilution risk is rated as low, with no immediate pressure for share issuance. Recent events and filings are not detailed in the provided data, but the company's financial performance suggests a challenging operating environment. The negative net income and operating income, combined with high debt levels, indicate a need for strategic adjustments to improve profitability and liquidity.